Last reviewed · How we verify
SD-101 Dermal Cream (6%)
SD-101 is a topical dermal cream formulation designed to treat skin conditions through a proprietary mechanism not publicly disclosed in detail.
SD-101 Dermal Cream (6%) is a topical treatment under development by Scioderm, Inc. for Epidermolysis Bullosa. It has completed Phase 2 trials and is currently in Phase 3. The cream aims to improve wound healing and reduce pain, with a focus on safety and efficacy.
At a glance
| Generic name | SD-101 Dermal Cream (6%) |
|---|---|
| Also known as | SD-101, SD-101-6.0, Zorblisa |
| Sponsor | Scioderm, Inc. |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
SD-101 at 6% concentration is being developed by Scioderm, Inc. as a dermatological therapeutic. The specific molecular mechanism and active pharmaceutical ingredient details are not widely available in public literature, limiting detailed mechanistic characterization at this phase of development.
Approved indications
- Dermatological indication (specific indication not publicly disclosed)
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SD-101 Dermal Cream (6%) CI brief — competitive landscape report
- SD-101 Dermal Cream (6%) updates RSS · CI watch RSS
- Scioderm, Inc. portfolio CI